LLF580, an FGF21 Analog, Reduces Triglycerides and Hepatic Fat in Obese Adults With Modest Hypertriglyceridemia

Area of Science:

• Metabolic disorders
• Pharmacology
• Biochemistry

Background:

• Obesity and hypertriglyceridemia are significant health concerns.
• Nonalcoholic fatty liver disease (NAFLD) is a growing public health issue.
• Fibroblast growth factor-21 (FGF21) analogs are being investigated for metabolic benefits.

Purpose of the Study:

• To assess the safety and efficacy of LLF580, a genetically engineered human FGF21 variant.
• Evaluate LLF580's impact on triglyceride levels, body weight, and liver fat reduction.
• Determine LLF580's effects on metabolic and liver health biomarkers.

Main Methods:

• A multicenter, double-blind, placebo-controlled trial.
• Obese adults with mild hypertriglyceridemia received LLF580 (300 mg) or placebo subcutaneously every 4 weeks for 3 doses.
• 61 participants completed the 12-week study.

Main Results:

• LLF580 significantly reduced triglycerides (54%), total cholesterol (7%), and LDL cholesterol (12%), while increasing HDL cholesterol (36%) compared to placebo (P < 0.001).
• A 52% reduction in liver fat was observed with LLF580, alongside improvements in liver enzymes and fibrosis markers (P < 0.001).
• LLF580 also improved insulin sensitivity and adiponectin levels, with generally mild gastrointestinal side effects.

Conclusions:

• LLF580 demonstrated significant improvements in serum lipids, liver fat, and liver injury biomarkers in obese, hypertriglyceridemic adults.
• The findings suggest LLF580's potential efficacy for treating hypertriglyceridemia and NAFLD.
• Further research is needed to confirm long-term safety and efficacy.